Adriana Valderrama

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0000-0003-4480-3879

发表论文 85 篇 · 总被引 1169 次 · h-index 15

代表论文

• Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 37)
• Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial (2025 · ESMO Open · 被引 5)
• Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA (2024 · Future Oncology · 被引 5)
• Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results. (2024 · Journal of Clinical Oncology · 被引 3)
• 1516P Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (2023 · Annals of Oncology · 被引 3)
• Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (2025 · Journal of Managed Care & Specialty Pharmacy · 被引 1)